HOWL

Announcements

Nothing here yet

Daily updates

• Werewolf Therapeutics completed $33 million divestiture of INDUCER assets to EMD SeronoAug 21, 2026

FDA designations

Nothing here yet

News

• Werewolf Therapeutics and Ambros Therapeutics announced a merger agreement alongside an oversubscribed $150 million private placementAug 21, 2026
• Werewolf Therapeutics receives fast track designation from U.S. FDA for WTX-124, an investigational therapy for cancer treatmentOct 8, 2025